UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A randomized, double-blind, placebo-controlled study of the effects of pomegranate extract on rising PSA levels in men following primary therapy for prostate cancer

Prostate cancer and prostatic diseases, 2015-09, Vol.18 (3), p.242-248

2015

Volltextzugriff (PDF)

Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet

Annals of oncology, 2018-01, Vol.29 (1), p.23-25

2018

Volltextzugriff (PDF)

2526 Immune responses and clinical data from STRIDE, a randomized, phase 2, open label study of sipuleucel-T with concurrent vs sequential enzalutamide administration in metastatic castrationresistant prostate cancer

European journal of cancer (1990), 2015-09, Vol.51, p.S483-S483

2015

Volltextzugriff (PDF)

MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure

Investigational new drugs, 2009-08, Vol.27 (4), p.379-386

2009

Volltextzugriff (PDF)

Phase II Trial of Neoadjuvant Nab-Paclitaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy

The Journal of urology, 2009-04, Vol.181 (4), p.1672-1677

2009

Volltextzugriff (PDF)

Long-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder Preserving Combined Modality Therapy for Muscle-Invasive Bladder Cancer: A Pooled Analysis of RTOG 9906 and 0233

International journal of radiation oncology, biology, physics, 2014-09, Vol.90 (1), p.S132-S132

2014

Volltextzugriff (PDF)

21LBA Atezolizumab in patients (pts) with locally-advanced or metastatic urothelial carcinoma (mUC): Results from a pivotal multicenter phase II study (IMvigor 210)

European journal of cancer (1990), 2015-09, Vol.51, p.S720-S720

2015

Volltextzugriff (PDF)

7014 POSTER DISCUSSION Evaluation of Circulating Tumour Cells (CTCs) in Chemotherapy-naive Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Receiving TAK-700, an Investigational 17,20-lyase Inhibitor

European journal of cancer (1990), 2011, Vol.47, p.S488-S488

2011

Volltextzugriff (PDF)

1697P Phase II randomized double-blind trial of axitinib (Axi) +/- PF 04518600, an OX40 antibody (PFOX) after PD1/PDL1 antibody (IO) therapy (Tx) in metastatic renal cell carcinoma (mRCC): Final analysis

Annals of oncology, 2024-09, Vol.35, p.S1017-S1017

2024

Volltextzugriff (PDF)

1803P Phase I/II study of bavdegalutamide, a PROTAC androgen receptor (AR) degrader in metastatic castration-resistant prostate cancer (mCRPC): Radiographic progression-free survival (rPFS) in patients (pts) with AR ligand-binding domain (LBD) mutations

Annals of oncology, 2023-10, Vol.34, p.S973-S974

2023

Volltextzugriff (PDF)

Locally advanced and metastatic bladder cancer

Current treatment options in oncology, 2001-10, Vol.2 (5), p.431-436

Dreicer, R

2001

Volltextzugriff (PDF)

Novel cytotoxic and biological agents for prostate cancer: Where will the money be in 2005?

European journal of cancer (1990), 2005-04, Vol.41 (6), p.954-964

2005

Volltextzugriff (PDF)

2365MO Study EV-103 cohort L: Perioperative treatment w/ enfortumab vedotin (EV) monotherapy in cisplatin (cis)-ineligible patients (pts) w/ muscle invasive bladder cancer (MIBC)

Annals of oncology, 2023-10, Vol.34, p.S1203-S1203

2023

Volltextzugriff (PDF)

LBA24 Cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of expanded cohort 6 of the COSMIC-021 study

Annals of oncology, 2021-09, Vol.32, p.S1299-S1300

2021

Volltextzugriff (PDF)

651O Phase II trial of pembrolizumab (P) in combination with sEphB4-HSA (B4) in previously treated metastatic urothelial carcinoma (mUC)

Annals of oncology, 2021-09, Vol.32, p.S678-S678

2021

Volltextzugriff (PDF)

Long term efficacy and QOL data of chemohormonal therapy (C-HT) in low and high volume hormone naïve metastatic prostate cancer (PrCa): E3805 CHAARTED trial

Annals of oncology, 2016-10, Vol.27, p.vi244-vi244

2016

Volltextzugriff (PDF)

Paclitaxel in Advanced Urothelial Carcinoma: Its Role in Patients with Renal Insufficiency and as Salvage Therapy

The Journal of urology, 1996-11, Vol.156 (5), p.1606-1608

1996

Volltextzugriff (PDF)

CDK12-altered prostate cancer: Clinical features and therapeutic outcomes to standard systemic therapies, PARP inhibitors, and PD1 inhibitors

Annals of oncology, 2019-10, Vol.30, p.v326-v327

2019

Volltextzugriff (PDF)

845PD - CDK12-altered prostate cancer: Clinical features and therapeutic outcomes to standard systemic therapies, PARP inhibitors, and PD1 inhibitors

Annals of oncology, 2019-10, Vol.30, p.v326-v327

2019

Volltextzugriff (PDF)

Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases: A double-blind, randomized dose-response study

Cancer, 2001-04, Vol.91 (7), p.1191-1200

2001

Volltextzugriff (PDF)

927P - Clinical outcomes by sex with atezolizumab (atezo) monotherapy in patients (pts) with locally advanced/metastatic urothelial carcinoma (mUC)

Annals of oncology, 2019-10, Vol.30, p.v372-v373

2019

Volltextzugriff (PDF)

927PClinical outcomes by sex with atezolizumab (atezo) monotherapy in patients (pts) with locally advanced/metastatic urothelial carcinoma (mUC)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Clinical outcomes by sex with atezolizumab (atezo) monotherapy in patients (pts) with locally advanced/metastatic urothelial carcinoma (mUC)

Annals of oncology, 2019-10, Vol.30, p.v372-v373

2019

Volltextzugriff (PDF)

Practice patterns in metastatic castration-resistant prostate cancer (mCRPC): Evidence from the veterans health administration

Annals of oncology, 2017-09, Vol.28, p.v277-v278

2017

Volltextzugriff (PDF)

845PDCDK12-altered prostate cancer: Clinical features and therapeutic outcomes to standard systemic therapies, PARP inhibitors, and PD1 inhibitors

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

1 – 25 von 197

Suche als RSS-Feed

Aktive Filter

ThemaFemale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(181)
Mit Volltextzugriff
(168)

Publikationsform

Sprache

Englisch
(197)

Erscheinungsjahr

n.n

Thema

Science & Technology
(71)
Humans
(66)
Life Sciences & Biomedicine
(65)
Male
(51)
Oncology
(40)
Biological And Medical Sciences
(30)
Medical Sciences
(29)
Middle Aged
(26)
Aged
(23)
Prostatic Neoplasms - Drug Therapy
(22)
Prostate Cancer
(20)
Treatment Outcome
(19)
Urology & Nephrology
(19)
Prostatic Neoplasms - Pathology
(18)
Tumors
(17)
Chemotherapy
(16)
Prostate-Specific Antigen - Blood
(15)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(14)
Nephrology. Urinary Tract Diseases
(13)
Pharmacology. Drug Treatments
(13)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

A randomized, double-blind, placebo-controlled study of the effects of pomegranate extract on rising PSA levels in men following primary therapy for prostate cancer

Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet

2526 Immune responses and clinical data from STRIDE, a randomized, phase 2, open label study of sipuleucel-T with concurrent vs sequential enzalutamide administration in metastatic castrationresistant prostate cancer

MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure

Phase II Trial of Neoadjuvant Nab-Paclitaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy

Long-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder Preserving Combined Modality Therapy for Muscle-Invasive Bladder Cancer: A Pooled Analysis of RTOG 9906 and 0233

21LBA Atezolizumab in patients (pts) with locally-advanced or metastatic urothelial carcinoma (mUC): Results from a pivotal multicenter phase II study (IMvigor 210)

7014 POSTER DISCUSSION Evaluation of Circulating Tumour Cells (CTCs) in Chemotherapy-naive Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Receiving TAK-700, an Investigational 17,20-lyase Inhibitor

1697P Phase II randomized double-blind trial of axitinib (Axi) +/- PF 04518600, an OX40 antibody (PFOX) after PD1/PDL1 antibody (IO) therapy (Tx) in metastatic renal cell carcinoma (mRCC): Final analysis

1803P Phase I/II study of bavdegalutamide, a PROTAC androgen receptor (AR) degrader in metastatic castration-resistant prostate cancer (mCRPC): Radiographic progression-free survival (rPFS) in patients (pts) with AR ligand-binding domain (LBD) mutations

Locally advanced and metastatic bladder cancer

Novel cytotoxic and biological agents for prostate cancer: Where will the money be in 2005?

2365MO Study EV-103 cohort L: Perioperative treatment w/ enfortumab vedotin (EV) monotherapy in cisplatin (cis)-ineligible patients (pts) w/ muscle invasive bladder cancer (MIBC)

LBA24 Cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of expanded cohort 6 of the COSMIC-021 study

651O Phase II trial of pembrolizumab (P) in combination with sEphB4-HSA (B4) in previously treated metastatic urothelial carcinoma (mUC)

Long term efficacy and QOL data of chemohormonal therapy (C-HT) in low and high volume hormone naïve metastatic prostate cancer (PrCa): E3805 CHAARTED trial

Paclitaxel in Advanced Urothelial Carcinoma: Its Role in Patients with Renal Insufficiency and as Salvage Therapy

CDK12-altered prostate cancer: Clinical features and therapeutic outcomes to standard systemic therapies, PARP inhibitors, and PD1 inhibitors

845PD - CDK12-altered prostate cancer: Clinical features and therapeutic outcomes to standard systemic therapies, PARP inhibitors, and PD1 inhibitors

Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases: A double-blind, randomized dose-response study

927P - Clinical outcomes by sex with atezolizumab (atezo) monotherapy in patients (pts) with locally advanced/metastatic urothelial carcinoma (mUC)

927PClinical outcomes by sex with atezolizumab (atezo) monotherapy in patients (pts) with locally advanced/metastatic urothelial carcinoma (mUC)

Clinical outcomes by sex with atezolizumab (atezo) monotherapy in patients (pts) with locally advanced/metastatic urothelial carcinoma (mUC)

Practice patterns in metastatic castration-resistant prostate cancer (mCRPC): Evidence from the veterans health administration

845PDCDK12-altered prostate cancer: Clinical features and therapeutic outcomes to standard systemic therapies, PARP inhibitors, and PD1 inhibitors

Aktive Filter

Suchergebnisse filtern